Innovus Pharma Announces the U.S. Launch of Sensum+®, a Clinically Proven Product to Increase Penile Sensitivity, on its Beyond Human Sales and Marketing Platform

Guía de Regalos

In a clinical trial, Sensum+® nearly doubled penile
sensitivity and tripled sexual satisfaction. Product Targets a ~$1
Billion Market.

SAN DIEGO–(BUSINESS WIRE)–Innovus
Pharmaceuticals
, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging commercial stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter medicine
and consumer care products
to improve men and women’s health and
respiratory diseases, today announced the launch of Sensum+® in the U.S.
An estimated 10-20 million men suffer from reduced penile sensitivity in
the U.S. due to diabetes complications according to the National
Institutes of Health (NIH Consensus Development Panel on Impotence. JAMA
1993; 270: 83-90. The neuropathy of erectile dysfunction, Nature,
December 2002, Volume 14, Number 6, Pages 433-439). That represents an
estimated market of more than $1 billion per year.

The product will be available through www.sensumplus.com
and through the Beyond Human print and online platform targeting between
20-30 million Americans on a monthly basis.

As previously announced, Sensum+® was tested in human survey use
clinical trial in circumcised men with low penile sensitivity.

We believe that results from the study showed statistically significant
increases in all endpoints measured including:

  1. 197% in penile sensitivity
  2. 60% reduction in time for Masturbation Ejaculatory Latency Time (MELT)
    in diabetic men
  3. Over 300% increase in satisfaction
  4. Close to 275% increase in Partner’s Satisfaction

We believe that the data also indicates that Sensum+® was well tolerated
with no serious adverse events reported.

Sensum+® is a proprietary patented topical formulation specifically
designed to increase penile sensitivity in-licensed from Centric
Research Institute.

“Sensum+® is the third Innovus product to be launched using our acquired
Beyond Human sales and marketing platform and we currently believe the
product could generate close to $2 million a year in revenues, adding to
the revenues already being generated by the success of our Vesele®
and RecalMax™ dietary supplements,” said Innovus CEO Dr.
Bassam Damaj
.

About Sensum+® and Reduced Penile Sensitivity (RPS)
Sensum+®
is a patented blend of essential oils and natural botanicals including
rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The
main ingredient of Sensum+® (cinnamon oil) works by activating the
Transient Receptor Potential A1 (TRPA-1) channels responsible for the
heat and cold sensation of the skin and results in an increase of
sensation that current users welcome and appreciate. The safety and
efficacy of Sensum+® was evaluated in two post marketing survey studies
in circumcised and non-circumcised men. A total of 382 men used Sensum+®
twice daily for 14 consecutive days followed by once daily for eight
weeks and as needed thereafter.

Reduced penile sensitivity is a major problem associated with many
diseases such as hernia surgery, the use of anti-depressants,
circumcision, multiple sclerosis and others. There are no approved
products to treat RPS.

For more information, visit www.sensumplus.com.

About Innovus Pharmaceuticals, Inc.
Headquartered in San
Diego, Innovus Pharma is an emerging leader in OTC and consumer products
for men’s and women’s health and respiratory diseases. The Company
generates revenues from its lead
products
(a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent,
(c) Zestra® for female arousal and (d) EjectDelay® for premature
ejaculation and has an additional five marketed products in this space,
including (e) Sensum+® for the indication of reduced penile sensitivity,
(f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health,
(h) Androferti® (in the US and Canada) to support overall male
reproductive health and sperm quality, (i) BTH Vision Formula, (j) BTH
Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic
Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com.

Innovus Pharma’s Forward-Looking Safe Harbor:
Statements
under the Private Securities Litigation Reform Act, as amended: with the
exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the
matters herein described for a variety of reasons that are outside the
control of the Company, including, but not limited to, projected
revenues from the Sensum+® product, projected online subscribers,
estimated market for its products, and statements about achieving its
other development, growth, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company’s most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and
other filings made with the SEC. Copies of these reports are available
from the SEC’s website or without charge from the Company.

Contacts

Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com